2023—2024年美国妊娠期妇女接种辉瑞呼吸道合胞病毒疫苗的安全性监测:疫苗不良事件报告系统(VAERS)分析
美国CDC与免疫实践咨询委员会于2023年9月推荐妊娠32—36周孕妇按季节接种辉瑞呼吸道合胞病毒(RSV)疫苗,以预防婴儿RSV相关下呼吸道疾病。本研究检索疫苗不良事件报告系统(VAERS)2023年8月20日至2024年6月3日的美国报告,共获121份妊娠期接种辉瑞RSV疫苗的报告,注射部位和全身反应见于44份(36%),妊娠特异性结局中最常见为早产37份(31%)和妊娠期高血压疾病9份(7%)。作者认为所报告的不良事件类型与上市前研究一致。
要点
- VAERS共收到121份妊娠期接种辉瑞RSV疫苗的报告,注射部位和全身反应44份(36%)。
- 妊娠特异性结局中最常见为早产37份(31%),妊娠期高血压疾病9份(7%)。
- 作者认为报告的不良事件类型与上市前研究一致,早产在报告中较常见。
核心结论
- 在辉瑞RSV疫苗获批并推荐用于妊娠期的美国首个RSV流行季,VAERS所报告的不良事件类型与上市前研究一致。
- 早产在报告中较常见;评估辉瑞母亲RSV疫苗与早产之间潜在关联的研究正在进行中。
- CDC与FDA将在未来流行季继续监测该疫苗的安全性。
研究设计与样本
- 研究为对VAERS被动监测系统所收报告的分析,检索2023年8月20日至2024年6月3日美国妊娠期接种辉瑞RSV疫苗后不良事件或接种差错的报告。
- 由临床医生审阅报告及可获得的病历资料。
主要发现
- VAERS共收到121份妊娠期接种辉瑞RSV疫苗的报告。
- 注射部位和全身反应见于44份报告(36%)。
- 妊娠特异性结局中最常报告的是早产37份(31%)和妊娠期高血压疾病9份(7%)。
关键数值与推荐
- 2023年9月,免疫实践咨询委员会与CDC推荐妊娠32—36周孕妇按季节接种辉瑞RSV疫苗,以预防6月龄以下婴儿RSV相关下呼吸道疾病(LRTD)。
- 在妊娠24—36周孕妇的临床试验中,辉瑞RSV疫苗接种者早产和妊娠期高血压疾病多于安慰剂组,但差异无统计学意义。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In September 2023, the Advisory Committee on Immunization Practices and the Centers for Disease Control and Prevention (CDC) recommended Pfizer's Respiratory Syncytial Virus (RSV) vaccine for pregnant women at 32-36 weeks' gestation using seasonal administration to prevent RSV-associated lower respiratory tract disease (LRTD) in infants aged <6 months. In clinical trials among pregnant women at 24-36 weeks' gestation, more preterm births and hypertensive disorders of pregnancy were noted among Pfizer's RSV vaccine recipients compared with placebo, but the differences were not statistically significant. Post-licensure safety monitoring of the Pfizer RSV vaccine in pregnant women is important to help inform immunization policies. OBJECTIVE: We assessed reports after Pfizer's RSV Vaccine in pregnant women submitted in the Vaccine Adverse Event Reporting System (VAERS), a passive surveillance system. METHODS: We searched VAERS for U.S. reports of adverse events (AEs) or vaccination errors in pregnant women vaccinated with the Pfizer RSV vaccine. We analyzed reports received from August 20, 2023 through June 3, 2024. Clinicians reviewed reports and available medical records. RESULTS: VAERS received 121 reports of pregnant women who received the Pfizer RSV vaccines. Injection site and systemic reactions were described in 44 (36 %) reports. The most commonly reported pregnancy-specific outcomes were preterm birth in 37 (31 %) and hypertensive disorders of pregnancy in 9 (7 %). CONCLUSIONS: During the first U.S. RSV season in which the Pfizer RSV vaccine was approved and recommended for use during pregnancy, the types of AEs reported were consistent with prelicensure studies. Preterm birth was described commonly in the reports. Studies assessing potential association between Pfizer's maternal RSV vaccine and preterm birth are ongoing. CDC and Food and Drug Administration (FDA) will continue to monitor the safety of this vaccine in future seasons.
引用
- Moro PL, Getahun A, Romanson B, et al. Safety monitoring of Pfizer's Respiratory Syncytial Virus Vaccine in pregnant women in the Vaccine Adverse Event Reporting System (VAERS), 2023-2024, United States. Vaccine. 2025. PMID: 40752249. doi:10.1016/j.vaccine.2025.127497
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。